Citi Pharma Limited

Pakistan listed pharmaceuticals sector’s earnings were up by 83% YoY to Rs8.0bn in 3QFY25. This jump in profitability is primarily attributed to higher net sales, improved gross margins, and a decline in finance cost.Net sales increased by 12% YoY to Rs85.5bn in 3QFY25, primarily driven by an increase in drug prices following the deregulation of non-essential drugs in Feb-2024. Haleon, ABOT, FEROZ, HPL, and AGP led the sector, showing strong sales growth in absolute terms.Thi ...

Citi Pharma Limited (CPHL) announced 3QFY25 result today where in company posted earnings of Rs220mn (EPS Re0.96) as compared to net earnings of Rs211 (EPS Re0.93) during the same period last year, up by 4%YoY. The earning slightly grew mainly due to expansion in gross margins and lower effective taxation.During 3QFY25, the company’s topline declined by 6%YoY to Rs3.3bn, primarily due to depressed international API prices, which are linked to falling crude oil prices. Additio ...

We analyse CY24 performance of the listed pharmaceutical sector, using a sample size of nine companies. The year remained positive for the sector, mainly due to stable currency and raw material prices, coupled with the deregulation of non-essential drug pricing, which enabled companies to pass on cost impacts as needed to ensure the availability of key drugs.During CY24, our sample companies cumulatively posted a significant topline growth of 20% YoY, reaching Rs297bn, mainly ...